Medical Strategy, Medical Affairs, and Product Launches ||| Systemic Organisational Constellations ||| Europe, EMEA + Asia.
Fourteen biotech companies spearheading the antibody drug conjugate industry. "The antibody-drug conjugate (ADC) field is witnessing an expansion in the variety of conjugation techniques, linker chemistry, and payloads being used, moving beyond traditional tubulin inhibitors to include novel mechanisms of action. Investments in ADC research continue to grow, with significant funding rounds and acquisitions. For example, Novo Holdings’ $105 million investment in Alentis Therapeutics showcases the ongoing efforts to enhance ADC development platforms. Additionally, the market’s geographical expansion, particularly in China, reflects a global push towards innovative cancer therapies, as evidenced by multiple collaborations and licensing agreements aiming to bring novel ADCs to the clinic. Here are some of the key biotech companies in the ADC landscape." AbbVie Adcendo Adcentrx Therapeutics Alentis Therapeutics Araris Biotech AG AstraZeneca / Daiichi Sankyo, Inc. BioNTech SE Bristol Myers Squibb GSK MBrace Therapeutics Oxford BioTherapeutics Pfizer / Seagen Roche Takeda https://lnkd.in/eNxJt5ff #biotech #antibodydrugconjugates
